The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-024-03668-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Mustafa Korkmaz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey. dr.musstafa@gmail.com. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Carcinoma, Renal Cell, Kidney Neoplasms, Receptors, Vascular Endothelial Growth Factor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Vascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a disease of advanced age and hypertension as a side effect of VEGF receptor inhibitors, beta-blocker use is common in these patients. We aimed to compare the treatment efficacy and survival results in case of concomitant use of these two drugs due to the inhibition of VEGF in beta-blockers. METHODS: A total of 121 patients with a diagnosis of mRCC who used sunitinib or pazopanib in first-line therapy were included in the study. These patients were divided into two groups as those using concomitant beta-blockers and those not using them. RESULT: The median overall survival (mOS) of the patient using sunitinib or pazopanib and concomitant beta-blocker was 47 (95% CI 29.0-65.0) months, and the mOS of those not using concomitant beta-blocker was 18 (95% CI 8.9-27.1) months (p < 0.001). The median progression-free survival (mPFS) of the patients using sunitinib or pazopanib and concomitant beta-blocker was 20.4 (95% CI 4.5-40.1) months, and the mPFS of those not using it was 11.4 (95% CI 5.9-16.9) months (p = 0.042). Concomitant beta-blocker use was found to be a good prognostic factor for OS in the multivariate analysis (p = 0.029). In the multivariate analysis, concomitant beta-blocker use had a trend towards statistical significance for PFS (p = 0.062). CONCLUSION: Concomitant use of betablockers with sunitinib or pazopanib is associated with longer overall survial and progression free survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey. dr.musstafa@gmail.com.
- Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey.
Zitieren
APA
Korkmaz, M., Eryılmaz, M. K., Koçak, M. Z., Er, M. M., Hendem, E., Demirkıran, A., Araz, M., & Artaç, M. (2024). The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03668-8
Vancouver
Korkmaz M, Eryılmaz MK, Koçak MZ, Er MM, Hendem E, Demirkıran A, et al. The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03668-8
BibTeX
@article{Korkmaz2024,
author = {Korkmaz, Mustafa and Eryılmaz, Melek Karakurt and Koçak, Mehmet Zahid and Er, Muhammed Muhiddin and Hendem, Engin and Demirkıran, Aykut and Araz, Murat and Artaç, Mehmet},
title = {The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-024-03668-8}
}
EUVIMED